Marker Therapeutics, Inc.
$1.67
▲
0.76%
2026-04-21 08:14:01
markertherapeutics.com
NCM: MRKR
Explore Marker Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$27.84 M
Current Price
$1.67
52W High / Low
$4.07 / $0.81
Stock P/E
—
Book Value
$1.01
Dividend Yield
—
ROCE
-74.05%
ROE
-68.81%
Face Value
—
EPS
$-0.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
1.47
Debt / Equity
—
Current Ratio
8.39
Quick Ratio
8.39
Forward P/E
-9.21
Price / Sales
8.23
Enterprise Value
$13.11 M
EV / EBITDA
—
EV / Revenue
3.7
Rating
None
Target Price
$7.87
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GT Biopharma, Inc. | $0.37 | — | $11.72 M | — | -214.65% | -13.77% | $3.85 / $0.35 | $0.23 |
| 2. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 3. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
| 4. | MetaVia Inc. | $1.51 | — | $7.13 M | — | -250.37% | -1.96% | $19.03 / $1.17 | $2.31 |
| 5. | Fulcrum Therapeutics, Inc. | $7.94 | — | $552.12 M | — | -24% | -25.3% | $15.74 / $2.92 | $5.24 |
| 6. | Quantum BioPharma Ltd. | $3.12 | — | $25.24 M | — | -300.19% | -3.47% | $52 / $2.85 | $1.81 |
| 7. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 6.59 M | — |
| Operating Profit | -1.88 M | -2.14 M | -4.26 M | -4.16 M | 2.73 M | — |
| Net Profit | -1.7 M | -2 M | -4.02 M | -4.45 M | -3.84 M | — |
| EPS in Rs | -0.1 | -0.12 | -0.24 | -0.27 | -0.23 | -0.26 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 3.31 M | 0 M |
| Operating Profit | -12.44 M | -11.12 M | -11.27 M | -19.79 M |
| Net Profit | -12.16 M | -10.73 M | -8.24 M | -29.93 M |
| EPS in Rs | -0.73 | -0.64 | -0.49 | -1.8 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.07 M | 22.02 M | 17.13 M | 34.42 M |
| Total Liabilities | 2.27 M | 3.46 M | 3.07 M | 14.82 M |
| Equity | 16.8 M | 18.56 M | 14.05 M | 19.6 M |
| Current Assets | 19.07 M | 22.02 M | 17.13 M | 16.62 M |
| Current Liabilities | 2.27 M | 3.46 M | 3.07 M | 7.78 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.01 M | -10.91 M | -16.44 M | -26.97 M |
| Investing CF | — | 0 M | 18.66 M | -4.95 M |
| Financing CF | 9.86 M | 14.99 M | 1.11 M | 0.2 M |
| Free CF | -12.01 M | -10.91 M | -16.44 M | -26.97 M |
| Capex | — | — | — | -4.95 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -30.28% | 72.48% | — | — |
| Profit Margin % | — | -248.76% | — | — |
| Operating Margin % | — | -340.37% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -340.37% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-01-27 | 1:0.1 |